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The RNASEL gene on chromosome 1q25 has been identified as a prostate cancer susceptibility gene. We screened for RNASEL
germline mutations in familial prostate cancer patients, and performed a case–control study to examine the association of specific
variants with prostate cancer risk in the Japanese. Three variants within the RNASEL gene, G282A, G1385A and T1623G were
identified. G1385 and T1623G variants result in previously reported Arg462Gln and Asp541Glu variants, respectively. The novel
G282A variant does not cause amino-acid substitution. A case–control study consisting of 101 familial prostate cancer cases and 105
noncancer controls showed that the Gln/Gln genotype of codon462 was observed in 7.6% of controls. However, the Gln/Gln
genotype was not observed in cases, and reduced prostate cancer risk (odds ratio (OR)¼0.061, P¼0.014). The Asp/Asp genotype
of codon541 increased the familial prostate cancer risk (OR¼7.37, P¼0.0004). In subset analysis, a significant association was
observed in patients with more than two affected members (OR¼3.15, P¼0.028), and weak associations were found in patients
with metastatic disease (OR¼2.40, P¼0.11) and high-grade disease (Gleason score X7) (OR¼3.07, P¼0.14). These findings
suggested that the polymorphic changes within the RNASEL gene may be associated with familial prostate cancer risk in a Japanese
population.
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Familial clustering of prostate cancer has been studied due to its
clinical significance as a high-risk group of prostate cancer (Carter
et al, 1992, 1993) and its genetic significance as a biological model
to identify susceptibility genes (Berthon et al, 1998; Berry et al,
2000; Bratt, 2000, 2002). Six prostate cancer susceptibility loci
(HPC1 at 1q24-25 (Smith et al, 1996), PCAP at 1q42-43 (Berthon
et al, 1998), HPCX at Xq27-28 (Xu et al, 1998), CAPB at 1p36
(Gibbs et al, 1999), HPC20 at 20q13 (Berry et al, 2000) and HPC2 at
17p12 (Tavtigian et al, 2001)) and two candidate susceptibility
genes (HPC2/ELAC2 at 17q (Tavtigian et al, 2001) and RNASEL at
1q24-25 (Carpten et al, 2002)) have been reported.
RNASEL was recently identified, and germline mutations were
cosegregated within families with prostate cancer linked to the
HPC1 region, at 1q24-25 (Carpten et al, 2002). In Finnish patients,
the truncation mutation at base pair position 793 (Glu265-stop)
was associated with hereditary prostate cancer (Ro ¨kman et al,
2002). Wang et al (2002) reported the association of the Arg462Gln
genotype with familial prostate cancer risk in a United States
population. RNASEL encodes the 20,50-oligoisoadenylate-synthe-
tase-dependent ribonuclease L protein (Zhou et al, 1993), and is
involved in the interferon-regulated 2-5A system that regulates cell
proliferation and apoptosis (Hassel et al, 1993; Castelli et al, 1998).
The incidence of prostate cancer was much lower in Japan in
comparison with the Western countries (Nakata et al, 1996).
However, it has been increasing annually, and the understanding
of the pathophysiology of this disease is warranted in Japan.
Although, the frequency of familial/hereditary prostate cancer
pedigrees is lower than that in Western countries (Ohtake et al,
1998; Ohtake et al, 2002), information on genetic characteristics of
Japanese familial/hereditary prostate cancer would be interesting
from the viewpoint of ethnic differences. In the present study, we
analysed RNASEL germline mutations in familial prostate cancer
in Japan, and investigated the significance of the RNASEL gene in
genetic susceptibility in a Japanese population.
MATERIALS AND METHODS
Patients
The present study included 101 prostate cancer patients with a
family history of prostate cancer. The numbers of affected family
members were two out of 72 patients, three out of 14 patients and
four out of 15 patients. In all, 29 patients with three or more
affected family members were categorised into hereditary prostate
cancer according to Carter’s criteria (Carter et al, 1993). Prostate
cancer was confirmed histologically at Gunma University Hospital
and its affiliated hospitals. Ages ranged from 40 to 88 years with a
mean age of 70.0 years. Clinical stages were A in 2, B in 41, C in 32,
D in 24 and unknown in two patients according to Jewett’s staging
system. Gleason scores were less than 7 in 25 and equal or greater
than 7 in 76 patients. Controls were recruited from outpatient
clinics at Gunma University Hospital. Controls were excluded if
they had an abnormal PSA level (i.e. 44.0ngml
 1), and abnormal
digital rectal examination, and a previous diagnosis of cancer. Ages
ranged from 51 to 88 years with a mean of 71.2 years. No Received 29 January 2003; revised 25 April 2003; accepted 30 April 2003
*Correspondence: Dr K Suzuki, E-mail: kazu@showa.gunma-u.ac.jp
British Journal of Cancer (2003) 89, 691–696
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
ssignificant differences in age were observed between cases and
controls. The Ethical Committee of Gunma University approved
this study, and all participants were enrolled under informed
consent.
Single-strand conformation polymorphism (SSCP) and
direct sequencing
Mutations in the coding sequence of six exons of the RNASEL gene
in familial prostate cancer patients were screened by the SSCP
method. The sequences for the PCR primers covering the coding
sequence for six exons were provided by Dr Carpten (the National
Human Genome Research Institute, National Institutes of Health).
Genomic DNA was isolated from whole blood using a GENOMIX
kit (Talent srl. Treisete, Italy). Samples were diluted to 10mgml
 1
and stored at  201C. PCR reactions were performed in a total
25mg reaction volume containing 20ng of genomic DNA, primers
(10mM of each forward and reverse primers), 1 PCR buffer
(1.5mM MgCl2,1 0m M Tris (pH 9.0), 50mM KCl and 0.1% Triton X-
100), dNTPs (20mM), and 1U of AmpliTaq Gold polymerase (PE
Applied Biosystems, Foster City, CA, USA). The PCR primer
amplification was performed in a GeneAmp
s 9700 thermalcycler
(PE Applied Biosystems). Cycling conditions were 951C for 10min
for one cycle; 941C for 30s, 601C for 30s, 721C for 30s for 35 cycle;
followed by an elongation cycle of 721C for 10min. PCR products
(3ml) were mixed with 7ml of denaturing solution (formamide with
10mM NaOH), were incubated at 951C for 5min, and were chilled
on ice immediately. Samples were electrophoresed at 6Vcm
 1 for
15h at 41C in GMAt (gene mutation analysis) Gels in 30mM Tris-
acetate EDTA (Elchrom Scientific AG, Switzerland). After electro-
phoresis, gels were stained with cyber-gold, and were visualised
under UV irradiation. To confirm the accuracy of bands detected
by the SSCP method, at least two PCR products were selected, and
were sequenced using an automated ABI Prism 310 Genetic
Analyzer (PE Applied Biosystems) according to the instructions of
the manufacturer. To facilitate the genotyping of Arg462Gln and
Asp541Glu polymorphisms of the RNASEL gene, we designed
primers covering these polymorphic sites. The sequences of
primers for Arg462Gln were 50-cac agc ggg aag tct ctt gt-30
(GenBank accession number NM_021133; nt 1202-1221); forward,
and 50-ggt ggg tgt atc cac agg ac-30 (GenBank accession number
NM_021133; nt 1450-1431); reverse. Those for Asp541Glu were 50-
ccttgagattcctcccatca-30 (GenBank accession number AL138776; nt
88952-88933); forward, and 50-ccaggatggaagagacgatg-30 (GenBank
accession number AL138776; nt 88701-88720); reverse.
Statistical analysis
The w
2 test was performed to evaluate whether the distribution of
genotype frequency of Arg462Gln and Asp541Glu polymorphisms
of the RNASEL gene varied among cases and controls. Odds ratios
(ORs) were calculated as an estimate of relative risk, and 95%
confidence intervals (CIs) were calculated from unconditional
logistic regression models. Genotypes were compared between
cases and controls. We also performed logistic regression analysis
whether clinical stage, pathological grade, age and number of
affected family members were associated with RNASEL genotypes.
The categories of clinical stage were localised (stages A–C) or
metastatic (stage D), and that of pathological grade was Gleason
score o7o rX7. Ages were divided into o70 or X70 years. The
SPSS Professional Statisticst (SPSS inc., Chicago, IL, USA) was
used for all statistical analyses.
RESULTS
Mutation screening of the coding sequence of six exons showed
one altered band in PCR product amplified by the primer set-1a. 2
(GenBank accession number NM_021133, nt 105-419), several
patterns in the primer set-1d (GenBank accession number
AL138776, nt 92278-91873) and the primer set-3 (GenBank
accession number AL138776, nt 88897-88565) (Table 1). Direct
sequencing revealed the G-A transition at base pair position 282
(Figure 1). In this patient, this transition caused no amino-acid
substitution (acg: Thr-aca:Thr). We performed three indepen-
dent PCR reactions and direct sequencing and confirmed the
G282A mutation. This patient was 64 years old at diagnosis of
G/G G/A
F-59 F-60
F-59
F-60
(I)
(II)
CCC C T AG
150 150
CC AN C C T
Figure 1 Detection of G282A mutation of the RNASEL gene. (I) An
aberrant pattern of SSCP was observed in F-60. The pattern of F-59, the
affected brother of F-60, was normal. (II) Direct sequencing showed G/A
heterozygous pattern of G282A in F-60. Wild-type G/G genotype was
observed in F-59.
Table 1 Analysis of the RNASEL gene is patients with familial prostate
cancer in Japan
Exon Codon Nucleotide change Amino-acid change
2 94 G282A None
2 462 G1385A Arg-Gln
4 541 G1623T Asp-Glu
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seven. No mutation was found in the affected brother (71 years at
diagnosis, stage C, Gleason score 6) of this patient and controls at
base pair position 282.
Direct sequencing of the primer set-1d and the primer set-3
showed Arg462Gln and Asp541Glu polymorphic sites, respectively
(Figures 2 and 3). In controls, Arg/Arg, Arg/Gln and Gln/Gln
genotypes were found in 71 (67.6%), 26 (24.8%) and 8 (7.6%),
respectively (Table 2). In familial prostate cancer cases, Arg/Arg
and Arg/Gln genotypes were found in 69 (68.3%) and 32 (31.7%),
respectively. No Gln/Gln genotype was found in any cases, and this
genotype tended to reduce prostate cancer risk (OR¼0.0061, 95%
CI¼0.035–0.11, P¼0.014). Regarding the Asp541Glu genotype,
Glu/Glu, Glu/Asp and Asp/Asp genotypes were found in 59
(56.2%), 43 (41.0%) and three (2.9%) in controls, respectively. In
cases, Glu/Glu, Glu/Asp and Asp/Asp genotypes were found in 51
(50.5%), 32 (31.7%) and 18 (17.8%), respectively. The Asp/Asp
genotype increased prostate cancer risk to a significant degree
(OR¼6.94, 95% CI¼3.98–12.10, P¼0.0009, in comparison with
the Glu/Glu genotype; OR¼7.37, 95% CI¼4.23–12.86, P¼0.0004,
in comparison with Glu/Glu þ Glu/Asp genotypes).
Stratification of cases according to clinical stage and patholo-
gical grade was performed (Tables 3 and 4). Although no
significant differences were observed in the Arg462Gln genotype
in the clinical stage, the Asp/Asp genotype of codon541 tended to
be frequently observed in patients with metastatic disease
(I) (II)
A
B
C
G/G
G/A
A/A
CAB
GG CCC AAAT
N C GC CA A A T
19
A C GC CA A A T
18
160
Figure 2 Detection of G1385A mutation of the RNASEL gene. (I) Three
patterns were observed by SSCP analysis (A–C). (II) Direct sequencing
showed G/G, G/A and A/A corresponding to A, B and C, respectively.
(I) (II)
C/C
A/C
A/A
A
B
C
ACB
T TT C C C C AG T TC
T TT C C C AGN T TC
T TT C C C AGA T TC
90 200
0 200
190
Figure 3 Detection of G1623T mutation of the RNASEL gene. (I) Three
patterns were observed in the analysis (A–C). (II) Direct sequencing
showed C/C, C/A and A/A corresponding to A, B and C, respectively.
Note that the sequences appearing in the figures are reverse complement
due to using the reverse primer for sequencing.
Table 2 Association of Arg462Gln and Asp462Gln genotypes of RNASEL with prostate cancer risk
No. of subjects (%)
Genotype Case Control OR (95% CI) P-value
Arg462Gln
Arg/Arg 69 (68.3%) 71 (67.6%) 1.0 (Ref.)
Arg/Gln 32 (31.7%) 26 (24.8%) 1.27 (0.73–2.21) 0.45
Gln/Gln 0 (0.0%) 8 (7.6%) 0.061 (0.035–0.11) 0.014
Asp541Glu
Glu/Glu 51 (50.5%) 59 (56.2%) 1.0 (Ref.)
Glu/Asp 32 (31.7%) 43 (41.0%) 0.86 (0.49–1.50) 0.62
Asp/Asp 18 (17.8%) 3 (2.9%) 6.94 (3.98–12.10) 0.0009
Glu/Glu+Glu/Asp 83 (82.2%) 102 (97.1%) 1.0 (Ref.)
Asp/Asp 18 (17.8%) 3 (2.9%) 7.37 (4.23–12.86) 0.0004
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Glu þ Glu/Asp genotypes) (Table 3). As for pathological grade, no
significant tendency was observed in the Arg462Gln genotype,
however, the Asp/Asp genotype of codon541 tended to be
frequently seen in patients with high-grade prostate cancer
(OR¼3.07, 95% CI¼1.76–5.35, P¼0.14, in reference with Glu/
GluþGlu/Asp genotypes) (Table 4). Stratification of subjects
according to age showed a similar tendency of distribution of both
the genotypes as demonstrated in Table 4 (data not shown). The
frequency of the Asp/Asp genotype of codon541 was significantly
higher in families with more than two affected members compared
with that in families with two affected members (OR¼3.15, 95%
CI¼1.81–5.49, P¼0.028, in comparison with Glu/GluþGlu/Asp
genotypes) (Table 5).
Table 3 Relation between Arg462Gln and Asp541Glu genotypes and pathological grade
No. of subjects (%)
Gleason score
Genotype o7 X7 OR (95% CI) P-value
Arg462Gln
Arg/Arg 19 (76.0%) 50 (65.8%) 1.0 (Ref.)
Arg/Gln 6 (24.0%) 26 (34.2%) 1.65 (0.94–2.87) 0.69
Gln/Gln 0 (0.0%) 0 (0.0%)
Asp541Glu
Glu/Glu 14 (56.0%) 37 (48.7%) 1.0 (Ref.)
Glu/Asp 9 (36.0%) 23 (30.3%) 0.97 (0.55–1.69) 0.95
Asp/Asp 2 (8.0%) 16 (21.1%) 3.03 (1.74–5.28) 0.16
Glu/Glu+Glu/Asp 23 (92.0%) 60 (78.9%) 1.0 (Ref.)
Asp/Asp 2 (8.0%) 16 (21.1%) 3.07 (1.76–5.35) 0.14
Table 5 Relation between Arg462Gln and Asp541Glu gennotypes and the number of affected family
members
No. of subjects (%)
No. of affected members
Genotype 2 42 OR (95% CI) P-value
Arg462Gln
Arg/Arg 49 (68.1%) 20 (69.0%) 1.0 (Ref.)
Arg/Gln 23 (31.9%) 9 (31.0%) 0.96 (0.55–1.67) 0.93
Gln/Gln 0 (0.0%) 0 (0.0%)
Asp541Glu
Glu/Glu 37 (51.4%) 14 (48.3%) 1.0 (Ref.)
Glu/Asp 26 (36.1%) 6 (20.7%) 0.61 (0.35–1.06) 0.37
Asp/Asp 9 (12.5%) 9 (31.0%) 2.64 (1.52–4.61) 0.08
Glu/Glu+Glu/Asp 63 (87.5%) 20 (69.0%) 1.0 (Ref.)
Asp/Asp 9 (12.5%) 9 (31.0%) 3.15 (1.81–5.49) 0.028
Table 4 Relation between Arg462Gln and Asp541Glu genotypes and clinical stage of prostate cancer
No. of subjects (%)
Genotype Localised Metastatic OR (95%CI) P-value
Arg462Gln 51 (68.%)
Arg/Arg 24 (32.0%) 17 (70.8%) 1.0 (Ref.)
Arg/Gln 0 (0.0%) 7 (29.2%)) 0.88 (0.50–1.53) 0.79
Gln/Gln 0 (0.0%)
Asp541Glu
Glu/Glu 39 (52.0%) 12 (50.0%) 1.0 (Ref.)
Glu/Asp 25 (33.3%) 5 (20.8%) 0.65 (0.37–1.13) 0.46
Asp/Asp 11 (14.7%) 7 (29.2%) 2.07 (1.19–3.61)) 0.21
Glu/Glu+Glu/Asp 64 (85.3%) 17 (70.8%) 1.0 (Ref.)
Asp/Asp 11 (14.7%) 7 (29.2%) 2.40 (1.37–4.18) 0.11
Two cases were excluded due to lack of staging information.
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sDISCUSSION
In the present study, we identified three variants within the
RNASEL gene among 101 patients with familial prostate cancer.
Two of them were previously reported variants, Arg461Gln and
Asp541Glu. We found one novel mutation of G–A transition at
codon94. This mutation does not cause amino-acid substitution,
and was not observed in the affected brother of the case.
Truncating mutation E265X was reported to cosegregate in high-
risk US families with hereditary prostate cancer (Carpten et al,
2002). E265X was also associated with hereditary prostate cancer in
Finnish patients (Ro ¨kman et al, 2002). In the present study, E265X
mutation was not observed in cases and controls. Rennert et al
(2002) found a novel founder mutation, 471delAAAG, in
Ashkenazi Jews, and reported that this mutation was associated
with prostate cancer risk in Ashkenazi men. In the present study,
this mutation was not observed in patients with familial prostate
cancer in Japan.
The most significant finding in the present study was the
association of the Asp541Glu genotype with prostate cancer risk.
In the Japanese population, the frequency of the wild-type Asp/Asp
genotype was rare (2.9% in controls), and the Glu541 variants were
prevalent in controls. We calculated ORs of Glu/Asp and Asp/Asp
genotypes in comparison with the Glu/Glu genotype as shown in
Table 2. The Asp/Asp genotype was significantly associated with
familial prostate cancer risk (P¼0.0004), with OR¼7.37. Further-
more, subset analysis showed that this significant association was
observed with more than two affected family members, that is,
hereditary prostate cancer (OR¼3.15, P¼0.028), and a weak
association was observed with metastatic stage disease (OR¼2.40,
P¼0.11) and high-grade (Gleason score X7) (OR¼3.07,
P¼0.14). These associations have not been reported by any other
studies (Casey et al, 2002; Ro ¨kman et al, 2002; Wang et al, 2002),
and might be a specific feature of familial prostate cancer
in Japan.
Another significant finding was the low frequency of the Gln462
variant in patients with familial prostate cancer. In the present
study, we did not find the Gln/Gln genotype in patients with
familial prostate cancer. The present findings supported the results
reported by Wang et al (2002). They observed that the low
frequency of the Gln 462 genotype was significantly associated with
familial prostate cancer. Subset analysis showed that this associa-
tion was observed in the younger group, localised stage group and
low-grade disease. However, we did not find any significant
differences in the frequencies of Arg/Arg and Arg/Gln genotypes in
subset analysis. On the other hand, Ro ¨kman et al (2002) reported a
higher, but not significant frequency, of the Gln462 variant.
Recently, Casey et al (2002) reported that the Gln462 variant has
three times less enzymatic activity than the wild type. They found
that the Gln462 variant is significantly associated with prostate
cancer risk. Controls in Casey’s study were nonaffected brothers,
however, those in other studies including the present study were
population-based controls (Ro ¨kman et al, 2002 ; Wang et al, 2002).
However, the exact reasons for discrepancies between these results
are unknown. Further studies will be necessary to confirm the
significance of the Arg462Gln genotype in the risk of familial
prostate cancer.
Limitations of the present study are the relatively small sample
number and the inclusion criteria of familial prostate cancer. We
started to collect familial prostate cancer pedigrees in 1994 (Ohtake
et al, 1998), and the frequency of familial prostate cancer was
about 3% (Ohtake et al, 2002). The incidence of prostate cancer in
Japan is markedly lower than those in Western countries (Nakata
et al, 1996), and the national awareness of prostate cancer has
increased only in these two decades. These situations have made it
difficult to diagnose prostate cancer at an early age, to identify
affected members in equal or more than three generations and
three members in one family. Due to these reasons, we enrolled
prostate cancer patients from at least two affected members in
families. The present study design used did not involve prospective
recruitment of study subjects into a study cohort. This point is
another limitation of the present study, and it could cause several
biases.
In summary, we found three variants within the RNASEL gene,
G282A, G1385A and T1623G. The G1385 and G1623T variants
result in previously reported Arg462Gln and Asp541Glu variants,
respectively. The G282A variant does not cause amino acid
substitution, and this mutation was identified for the first time.
A case–control study showed that the Gln/Gln genotype of
codon462 was not observed in cases, and reduced prostate cancer
risk to a significant degree. The Asp541Glu genotype had a marked
association with familial prostate cancer risk. The Asp/Asp
genotype increased the familial prostate cancer risk, and was
associated with risk of patients with many affected family
members. These associations need further large-scale and pro-
spective studies to confirm the consequences of the RNASEL gene
on familial prostate cancer.
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